NeoGenomics Q4 Earnings Call Highlights

For full-year 2025, NeoGenomics reported total revenue of $727 million , up 10% versus 2024. Clinical revenue increased 15% (or 13% excluding the PathLine acquisition), while non-clinical revenue declined 24% for the year. Adjusted gross profit increased $23 million , or 8% , to $335 million , and adjusted EBITDA rose 9% to $43.4 million . Cash flow from operations was positive $5 million in 2025, and the company reported that free cash flow improved by over 35% compared with 2024.Chief Financial Officer Je ...